Sydney, Australia – 14 March 2019 – Recce Pharmaceuticals Ltd (ASX:RCE) (Recce or the Company), the Company developing a new class of broad spectrum synthetic antibiotics, today announced the US Patents and Trademarks Office had Granted 23 claims for patent US 10,226,482 B2, ‘Copolymer and Method for Treatment of Bacterial Infection’.
The USA represents close to half of the world’s USD $42.33 billion antibiotic market by value(1). This patent is Recce’s second wholly owned patent to be Granted in USA and secures significant and additional monopolies for Recce to November 2035.
The Granted patent contains a suite of 23 claims including its lead candidate RECCE® 327.
Recce’s commercialisation strategy is focused on leveraging its expanding local and international intellectual property estate.
(1) Allied Market Research (October 2018): Global Opportunity Analysis and Industry Forecast, 2018 - 2025
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of a new class of synthetic antibiotics with broad spectrum activity designed to address the urgent global health problem of antibiotic resistant superbugs.
Its patented lead candidate known as RECCE® 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms. Pre-clinical testing in laboratories and animal models, in Australia and overseas has demonstrated positive results.
Recce has a manufacturing facility in Australia and is developing clinical research partners in the USA. The Company has developed an automated process to manufacture its lead compound ahead of first-in-human clinical trials.
Find out more at www.recce.com.au, or connect with us via Twitter @ReccePharma and LinkedIn.
Issued for and on behalf of Recce by Instinctif Partners.
For more information please contact: firstname.lastname@example.org